Wells Fargo analyst Derek Archilla is reiterating an Overweight rating on Ventyx Biosciences’ (VTYX) shares with a price target of $77 after Johnson & Johnson (JNJ)/Protagonist Therapeutics’ (PTGX) abstract for its oral IL-23 program was posted. The firm views this as the clearing event Ventyx Biosciences’ shares needed and likes the setup ahead of its second half of 2023 catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Ventyx Biosciences management to meet virtually with Piper Sandler
- Ventyx Biosciences initiates dosing in Phase 1 trial of VTX3232
- Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
- Ventyx Biosciences assumed with an Outperform at Credit Suisse
- Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis